Canakinumab

Generic Name: Canakinumab

Brand Names: Ilaris

Canakinumab is an IL-1β blocker for periodic fever syndromes, gout, and systemic juvenile idiopathic arthritis.

RheumatologicBiologic

Drug Class

Anti-IL-1β (Interleukin-1 Beta) Monoclonal Antibody

Pregnancy

Category C — Animal reproduction studies have shown adverse effects at doses higher than human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Available Forms

Subcutaneous injection solution (150 mg/mL single-use vial), Subcutaneous injection lyophilized powder for reconstitution (180 mg vial)

What It's Used For

Dosage Quick Reference

These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.

Condition	Starting Dose	Maintenance Dose
Cryopyrin-Associated Periodic Syndromes (CAPS) — adults and children >= 40 kg	150 mg SC every 8 weeks	150 mg SC every 8 weeks; may increase to 300 mg if inadequate response
CAPS — children 15–40 kg	2 mg/kg SC every 8 weeks	2 mg/kg every 8 weeks; may increase to 3 mg/kg
Systemic Juvenile Idiopathic Arthritis (sJIA)	4 mg/kg SC (max 300 mg) every 4 weeks	4 mg/kg SC every 4 weeks
Gout flares (refractory)	150 mg SC as a single dose	150 mg SC per flare; not more frequently than every 12 weeks

Side Effects

Common Side Effects:

Nasopharyngitis
Diarrhea
Upper respiratory infections
Injection site reactions
Headache
Nausea
Weight gain
Musculoskeletal pain

Serious Side Effects:

Serious infections (bacterial, viral, fungal)
Macrophage activation syndrome (in SJIA)
Hypersensitivity reactions
Neutropenia
Immunosuppression
Potential malignancy risk

Drug Interactions

Canakinumab modulates the immune system by neutralizing IL-1β, and drug interactions are primarily immunological in nature.

Live vaccines: Canakinumab suppresses IL-1β-mediated immune responses. Administration of live or live-attenuated vaccines is contraindicated during treatment due to the risk of disseminated vaccine infection. Ensure all vaccinations are current before initiating therapy.
TNF inhibitors (e.g., etanercept, adalimumab, infliximab): Concurrent use of canakinumab with other biologic immunomodulators increases the risk of serious infections without demonstrated additional efficacy. Avoid combining biologic therapies.
Other IL-1 blockers (e.g., anakinra, rilonacept): Overlapping IL-1 pathway inhibition provides no added benefit and substantially increases the risk of immunosuppression and serious infections. Do not use concurrently.
CYP450 substrates with narrow therapeutic indices (e.g., warfarin, cyclosporine, theophylline): IL-1β can suppress CYP450 enzyme expression during inflammation. When canakinumab reduces IL-1β levels, CYP450 activity may normalize, potentially altering the metabolism and blood levels of these medications. Monitor drug levels or effects upon initiation or discontinuation of canakinumab.

Additional Information

Canakinumab is a human monoclonal antibody that selectively blocks interleukin-1 beta (IL-1β), a pro-inflammatory cytokine central to many autoinflammatory conditions. This biologic medication provides targeted treatment for several rare inflammatory diseases and has shown promise in reducing cardiovascular events.

Mechanism of Action

Canakinumab specifically binds to human IL-1β with high affinity, neutralizing its biological activity by blocking its interaction with IL-1 receptors. IL-1β is a key mediator of inflammatory responses, and its overproduction is central to the pathogenesis of autoinflammatory diseases. By selectively blocking IL-1β (without affecting IL-1α or the IL-1 receptor antagonist), canakinumab provides targeted suppression of IL-1β-driven inflammation. This results in rapid reduction of inflammatory markers such as C-reactive protein (CRP), serum amyloid A, and various clinical symptoms associated with autoinflammatory conditions.

Available Formulations

Canakinumab is available as a lyophilized powder for reconstitution (180 mg vials) and as a solution for subcutaneous injection in single-use vials (150 mg/mL). The reconstituted solution or prefilled syringe should be administered by a healthcare provider or trained individual. The medication requires refrigeration.

Medical Uses

Canakinumab is FDA-approved for Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS); systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older; and active Still's disease, including adult-onset Still's disease. It is also approved for treating periodic fever syndromes including Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), and Familial Mediterranean Fever (FMF). The CANTOS trial also demonstrated reduced cardiovascular events in high-risk patients.

Dosing Guidelines

Dosing varies by indication. For CAPS: 150 mg (or 2 mg/kg for patients 15-40 kg) subcutaneously every 8 weeks. For SJIA: 4 mg/kg (maximum 300 mg) subcutaneously every 4 weeks. For Still's disease: 4 mg/kg (maximum 300 mg) subcutaneously every 4 weeks. For periodic fever syndromes: 150 mg (or 2 mg/kg for patients ≤40 kg) every 4 weeks, with possible increase to 300 mg or every 4-week dosing if needed. Responses are typically seen within days to weeks.

Important Safety Information

Canakinumab increases the risk of serious infections, including opportunistic infections. Treatment should not be initiated during active infections, and patients should be monitored closely. Tuberculosis screening is required before starting therapy. Live vaccines should not be given during treatment; all recommended vaccinations should be completed before starting therapy. Macrophage activation syndrome (MAS), a potentially fatal condition, has been reported in SJIA patients. Hypersensitivity reactions may occur.

Drug Interactions

IL-1 blockade may affect the expression of CYP450 enzymes. When starting or stopping canakinumab, therapeutic monitoring should be performed for medications metabolized by CYP450 with narrow therapeutic indices (warfarin, cyclosporine, theophylline). Concurrent use with TNF inhibitors is not recommended due to increased infection risk. Live vaccines should not be administered during treatment. No formal drug interaction studies have been conducted.

Special Populations

There are limited data on use during pregnancy; animal studies showed no evidence of harm. The medication should be used during pregnancy only if clearly needed. It is unknown whether canakinumab is excreted in human breast milk. Safety and efficacy have been established in pediatric patients for CAPS (4 years and older) and SJIA (2 years and older). Clinical trials included limited numbers of elderly patients; no overall differences in safety were observed. No dose adjustment is needed for renal impairment. The medication has not been studied in patients with hepatic impairment.

Frequently Asked Questions

Canakinumab is a fully human monoclonal antibody that specifically targets interleukin-1 beta (IL-1β), a single pro-inflammatory cytokine. Unlike NSAIDs or corticosteroids, which broadly suppress inflammation, canakinumab precisely blocks one key mediator. This targeted approach is particularly effective in autoinflammatory conditions driven by IL-1β overproduction, such as cryopyrin-associated periodic syndromes.

Canakinumab is given as a subcutaneous (under the skin) injection, typically in the upper thigh, abdomen, or upper arm. For CAPS and sJIA, injections are scheduled every 4 to 8 weeks depending on the condition. After training, patients or caregivers may administer injections at home, though the first dose is usually given under medical supervision.

Because canakinumab suppresses part of the immune response, you should promptly report fever, chills, persistent cough, painful or frequent urination, unusual fatigue, or any wound that appears red, swollen, or slow to heal. Even mild symptoms that do not resolve should be evaluated, as IL-1β blockade can mask the typical inflammatory signs of infection.

The CANTOS trial (2017) demonstrated that canakinumab reduced recurrent cardiovascular events in patients with prior heart attack and elevated C-reactive protein levels, supporting the inflammatory hypothesis of atherosclerosis. However, canakinumab is not currently FDA-approved for cardiovascular indications. Its approved uses remain CAPS, systemic JIA, and refractory gout flares.

Yes. Your doctor should order regular blood tests including a complete blood count (CBC), C-reactive protein (CRP), and liver function tests. Before starting therapy, you should be screened for tuberculosis and hepatitis B. Vaccinations should be brought up to date before the first dose, and live vaccines must be avoided during treatment.

Questions to Ask Your Doctor

Consider discussing these topics at your next appointment:

✓What specific tests will you use to monitor my response to canakinumab and check for side effects?
✓Are my vaccinations up to date, and are there any I need before starting this medication?
✓What should I do if I develop signs of an infection between scheduled appointments?
✓How long will I need to stay on canakinumab, and what would indicate the treatment is or is not working?
✓Are there any lifestyle modifications or complementary treatments that could support my response to therapy?

Schedule an Appointment

Related Health Conditions

This medication is commonly used to treat or manage the following conditions:

Hives (Urticaria)

Hives (urticaria) are itchy, raised welts caused by histamine release, triggered by allergens, physical stimuli, medications, infections, stress, or sometimes, unknown factors.

Learn More

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.